As a consequence, recent guidelines have recommended limiting the systematic use of prostate cancer screening based on prostate-specific antigen (PSA) testing to avoid overdiagnosis and overtreatment [1], [2], [3], [4]. The gene discussed is KLK3; the disease is Familial prostate cancer.